Publisher's Synopsis
Although respiratory complications are the major cause of morbidity and mortality in cystic fibrosis (CF), the outlook for patients is improving considerably due to advances in the study and therapy of the disease. This book offers recent perspectives on the status of inhaltion therapy, as well as the pathophysiological procesess underlying CF pulmonary disease.;These papers review the effectiveness of both well-established inhalation therapies and novel therapies such as rhDNase. Also discussed are various factors which may optimize or compromise the efficient delivery of such treatments. Information on the effects of different drug/nebulizer combinations and the clinical benefits or hazards of inhalation antibiotic therapy is provided.
